Creo Medical offers a high-risk, high-upside medtech re-rating opportunity as disruptive endoscopic energy technology begins converting clinical validation into commercial scale.
Overview
Creo Medical is a UK medtech company aiming to transform surgical endoscopy through its Kamaptive advanced-energy platform, enabling complex GI and lung procedures to move from operating rooms to endoscopy suites. Revenue comes from CROMA hardware, recurring high-margin single-use consumables, and strategic licensing. Following the 2025 sale of 51% of its European distribution arm, Creo is focused on its higher-growth core technology business. FY25 revenue rose 50% to £6.0m, Q1 FY26 grew around 60%, and operating losses are narrowing materially.